asco@alo33:161970 JSONTXT

Background: Considering the high prevalence of comorbidities in multiple myeloma MM patients, comorbidity has an important issue for the management of myeloma. Hoever, the impact of comorbidity on clinical outcomes has not been fully investigated. We retrospectively analyzed patients ith myeloma treated ith autologous stem cell transplantation. Comorbidities ere assessed based on the Charlson comorbidity index CCI , Hematopoietic stem cell transplantation comorbidity index HCT-CI and Performance status ith ECOG and Karnofsky index. Methods: A total of 110 patients ith MM treated ith autologous stem cell transplantation ere analyzed beteen 2000 and 2015. Comorbid conditions and disease-related complications ere examined during autologous stem cell transplantation and stem cell mobilization and the impact on overall survival OS and non-relapse mortality NRM . Results: Age of transplanted MM patients as median 52 years range 40-65 ith median 13 months range 4-46 from diagnosis to transplant. At transplant setting 40 percent of patients had lo HCT-CI, 56 percent ere ith intermediate HCT-CI and 29 percent ere ith high HCT-CI. According to CCI 64 percent of patients had score 2, 22 percent ere ith score 3 and 13 percent of patients score 4. ECOG as 0 in 79 percent of MM patients treated ith autologous transplantation. Factors that affect overall survival OS in autologous MM recipients ere: HCT-CI, Karnofsky score, number of CD34+cellskg and time from diagnosis until transplant p lt 0.05 . Factors that affect TRMNRM ere HCT-CI, ECOG, Karnofsky, number of hospital days and body eight p lt 0.05 . Conclusions: MM treatment patterns have been dynamic over time. Comorbid conditions and myeloma-related complications increase as patients progress and may orsen MM patientsx0027; prognoses over time. A comprehensive assessment of comorbidity can help to explain the huge heterogeneity of myeloma outcome.,J Clin Oncol 34, 2016 suppl; abstr 8023 00:00.0,Hematologic MalignanciesPlasma Cell Dyscrasia